Author Affiliations: Department of Preventive Medicine, University of Tennessee Health Science Center (Drs Klesges, Johnson, and Somes); and Division of Epidemiology and Cancer Control, St Jude Children's Research Hospital (Dr Klesges), Memphis.
In this issue of JAMA, Gonzales and colleagues,1 Jorenby and colleagues,2 and Tonstad and colleagues3 report the results of 3 randomized trials on the efficacy of the nicotinic acetylcholine receptor partial agonist varenicline for achieving smoking cessation. For the clinician and the lay public, the major question from these trials is simply this: How effective and useful is varenicline for smoking cessation?
Klesges RC, Johnson KC, Somes G. Varenicline for Smoking CessationDefinite Promise, But No Panacea. JAMA. 2006;296(1):94-95. doi:10.1001/jama.296.1.94